Objective:
Bipolar I disorder (BD-I) is a type of bipolar spectrum disorder characterized by manic or mixed episodes. Detecting microRNA regulations as epigenetic actors in BD-I is important to elucidate the pathogenesis of the disease and reveal the potential of microRNAs (miRNAs) as biomarkers.
Methods:
We evaluated the expression profile of six candidate miRNAs (
hsa-miR-145-5p
,
hsa-miR-376a-3p
,
hsa-miR-3680-5p
,
hsa-miR-4253-5p
,
hsa-miR-4482-3p
, and
hsa-miR-4725
) in patients with BD-I and in healthy controls (aged 11-50 years). We also determined the potential target genes of these miRNAs through
in silico
analysis. The diagnostic values of the miRNAs were calculated through receiver operating characteristic curve analysis.
Results:
Four miRNAs were upregulated (
hsa-miR-376a-3p
,
hsa-miR-3680-5p
,
hsa-miR-4253-5p
,
hsa-miR-4482-3p
) and
hsa-miR-145-5p
was downregulated in patients (p < 0.001). The target gene analyses showed that
hsa-miR-145-5p
specifically targets the dopamine decarboxylase (
DDC
) gene. The area under the curve of
hsa-miR-145-5p
was 0.987.
Conclusion:
Differential expression of five miRNAs in peripheral blood may be associated with the pathogenesis of BD-I, and
hsa-miR-145-5p
has potential as a BD-I biomarker. This miRNA can be used in dopamine-serotonin regulation and dose adjustment in drug therapy via the
DDC
gene.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.